IndraLab

Statements

Pralnacasan inhibits CASP1. 3 / 3
| 3
reach
"Pralnacasan, an orally absorbed nonpeptide compound, can inhibit caspase-1."
38177104
reach
"Pralnacasan, an orally available non-peptide compound, inhibits caspase-1, reducing joint damage in osteoarthritis models and mitigating colitis in mice [136, 137]."
40155968
reach
"OLT1177, a β-sulfonyl nitrile compound, inhibits the NLRP3 inflammasome activation and Pralnacasan (VX740), a selective non-peptide, inhibits the conversion of pro-caspase-1 to its functional form, pr[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
35696852